ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Analysis limitations: These analyses are exploratory in nature and definitive conclusions should not be drawn.
The standard regimens consisted of 5 antimyeloma treatment options: DPd, DVd, IRd, Kd, or EPd, selected by Investigator contingent upon the patient’s most recent antimyeloma treatment.2
Efficacy based on follow-up at the primary PFS analysis (median follow-up of 15.9 months (95% CI, 14.1-18.0)).2
NC=not calculated; PI=proteasome inhibitor; R-ISS=Revised International Staging System.